Survival analysis in patients with pulmonary metastatic renal cell carcinoma (MRCC) treated by inhaled interleukin-2 (IL-2) compared to prognostic stratification models

By Heinzer H.   Toma M.   Huland E.   Huland H.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 99-99

Elsevier

Access to resources Recommend Favorite

Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial - clinical data and laboratory evidence of protease activation

By Igarashi T.   Marumo K.   Onishi T.   Kobayashi M.   Aiba K.   Tsushima T.   Ozono S.   Tomita Y.   Terachi T.   Satomi Y.   Kawamura J.  

Urology, Vol. 53, Iss. 1, 1999-01 ,pp. : 53-59

Elsevier

Access to resources Recommend Favorite

Lymphocyte subpopulations: prognostic value of patients with renal cell carcinoma under therapy with IL-2 and IFN-alpha

By Hillig F.   Schneider T.   Zacharias M.   Langner J.   Fornara P.  

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 141-141

Elsevier

Access to resources Recommend Favorite

Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma

By Kriegmair M.   Oberneder R.   Hofstetter A.  

Urology, Vol. 45, Iss. 5, 1995-05 ,pp. : 758-762

Elsevier

Access to resources Recommend Favorite

Predicting survival of patients with metastatic renal cell carcinoma

By Motzer R.   Mazumdar M.  

Der Urologe A, Vol. 43, Iss. 3, 2004-09 ,pp. : 135-136

Springer Publishing Company

Access to resources Recommend Favorite